Olssa (Olmesartan Medoxomil, Amlodipine)

Olssa combines olmesartan medoxomil and amlodipine to address cardiovascular conditions that involve the renin‑angiotensin system and calcium‑channel mediated vascular tone.

• Hypertension: helps lower systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertensive heart disease: assists in preventing left‑ventricular hypertrophy associated with long‑term high blood pressure.
• Chronic kidney disease with hypertension: aids in slowing renal function decline by maintaining target blood pressure levels.

• Olmesartan medoxomil blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle cells, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx through L‑type channels in arterial smooth‑muscle, promoting vasodilation. The combined effect produces additive reduction of peripheral resistance and blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially on standing.
• Flushing: transient warmth or redness.
• Fatigue: general feeling of tiredness.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips, tongue or throat.
• Severe hypotension: symptomatic low blood pressure.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Acute kidney injury: sudden reduction in renal function.
• Heart block or severe bradycardia: markedly slow heart rate.
• Allergic rash or Stevens‑Johnson syndrome: severe skin reactions.

Before initiating Olssa, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Hepatic function: check liver enzymes in patients with liver disease.
• Electrolytes: monitor potassium and sodium levels, especially if combined with diuretics.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Concomitant antihypertensives: watch for additive blood‑pressure lowering effects.
• Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olssa may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Aliskiren: concurrent use in diabetic patients can increase risk of renal impairment and hyperkalaemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function.
• Lithium: increased lithium concentrations may occur.
• Rifampicin: may reduce amlodipine exposure, lowering efficacy.